Aggrecan Antibody, N-terminal neoepitope FFGV
Please register to view price.
North America: 1-888-USMDBIO
International: +41-44 986 2628
Or you can order by using our online form
Have questions or need bulk? No problem, just ask.
Aggrecan monoclonal antibody to N-terminal neoepitope FFGV (mouse, clone BC14). This fragment is rapidly released from the tissue when MMP catabolism of aggrecan occurs and has been identified in synovial fluid samples from patients with degenerative joint diseases.
Overview
Proteoglycans are categoried depending upon the nature of their glycosaminoglycan chains (chondroitin sulfate, dermatan sulfate, heparan sulphate and keratan sullfate) as well as characterized by size.
Aggrecan is a large aggregating proteoglycan of articular cartilage. It is found also in aorta tissue, discs, tendons and in the perineuronal net. It is responsible for hydrating cartilage, giving it compressibility and resiliance during joint loading, thereby playing a major role in the normal function of cartilage. Depletion of glycosaminoglycan bearing aggrecan fragments is one of the earliest events in cartilage destruction.
Data/Specifications
Immunogen: Synthetic peptide: FFGVGGE
Clone: BC-14
Host: Mouse
Myeloma: x63-Ag8.653
Isotype: IgG2a
Light Chain type: kappa
Specificity: Recognizes the N-terminal neoepitope sequence (FFGV....) generated at the “MMP cleavage site” after MMP catabolism in the interglobular domain of aggrecan between amino acids ..PEN341 and 342FFG.. (Human sequence enumeration).
Cross-reactivity: This antibody cross-reacts with human, Rat, guinea pig, horse, and Pig.
Purity: Affinity purified on protein G
Form: Liquid, 1 mL/vial
Concentration: 0.1 mg/mL
Storage: -20° C
Literature/Support
Aggrecan Antibody, clone BC14 (PDF, 333KB)
Joint Disease and Aggrecan (blog post)
How To Use
- Western-Blotting - Suggested dilution: 1:100. Detects a a band of approximately 60 - 150 kDa
- ELISA
- IHC
Technical Notes:
This antibody should work in IHC on formalin- or paraformaldehyde-fixed paraffin embedded
sections as well as either alcohol-fixed frozen sections or un-fixed snap-frozen sections.
Samples are usually deglycosylated using 0.01 Units Chondroitinase ABC (Sigma), 0.01
Units Keratanase (Seikagaku) and 0.0001 Units Keratanase II (Seikagaku) per 10μg S-GAG
of non-deglycosylated aggrecan for optimal epitope recognition in SDS-PAGE and immunohistochemistry.